<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176826</url>
  </required_header>
  <id_info>
    <org_study_id>UMN-MT2000-21</org_study_id>
    <secondary_id>0010M66781</secondary_id>
    <nct_id>NCT00176826</nct_id>
    <nct_alias>NCT00973843</nct_alias>
  </id_info>
  <brief_title>T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders</brief_title>
  <official_title>In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and
      antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in
      the treatment of immune deficiencies and histiocytic disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will begin chemotherapy as a preparative regimen, which is intended to completely
      eliminate their defective immune system and bone marrow. The preparative regimen consists of
      the chemotherapy drugs (busulfan, cyclophosphamide, and antithymocyte globulin (ATG)).

      Transplantation: subjects will then have a source of blood stem cells (bone marrow) from
      their donor administered into their catheter. Medication will be given to help prevent
      Graft-Versus Host Disease (GVHD). The ATG will help to deplete the donor stem cells of the
      type of cells that can cause GVHD and will also help to promote engraftment of the new stem
      cells.

      Recovery Phase: The second phase of treatment consists of a period after transplantation
      during which we wait for the return of bone marrow function. This usually takes two to four
      weeks. Subjects will be given a blood cell growth factor, G-CSF, to help speed recovery of
      the white blood cells and potentially decrease the risk of infection and decrease the time
      until the bone marrow recovers.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Replaced by another protocol
  </why_stopped>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Transplant Engraftment</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Treatment Related Mortality.</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Surviving (Disease-free)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade II-IV Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Graft Failure</measure>
    <time_frame>Day 100 Post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With III-IV Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Surviving (Disease-free)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <condition>X-Linked Lymphoproliferative Disorders</condition>
  <condition>Chediak-Higashi Syndrome</condition>
  <condition>Griscelli Syndrome</condition>
  <condition>Immunologic Diseases</condition>
  <condition>Langerhans-Cell Histiocytosis</condition>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Intent-To-Treat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.</description>
    <arm_group_label>Intent-To-Treat</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myeloablative conditioning regimen</intervention_name>
    <description>Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
    <arm_group_label>Intent-To-Treat</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient from birth to &lt; 55 years of age fulfilling the following criteria will be
             eligible for this study.

          -  Patients meeting clinical diagnostic criteria for Hemophagocytic Lymphohistiocytosis
             (HLH)

          -  Patients meeting clinical diagnostic criteria or genetic diagnosis of X-linked
             lymphoproliferative disorder (XLP) and whose disease is ACTIVE but STABLE, or
             NON-ACTIVE/QUIESCENT.

          -  Patients with Chediak-Higashi Syndrome who meet the following diagnostic criteria and
             whose disease is ACTIVE but STABLE, or NON-ACTIVE/QUIESCENT as defined in Appendix V
             of the study protocol.

          -  Patients with Viral Associated Hemophagocytic Syndrome (VAHS) - if relapsed after
             other therapy or supportive care. Diagnostic criteria as above for HLH. Disease status
             must be ACTIVE but STABLE, or NON-ACTIVE/QUIESCENT as defined in Appendix V. It is
             cautioned that many patients with HLH or familial hemophagocytic lymphohistiocytosis
             (FHL) will have a viral infection at time of initial presentation and may therefore be
             misdiagnosed as having VAHS.

          -  Griscelli Syndrome

          -  Primary immune deficiencies with non-genotypic identical donors only.

          -  Progressive Langerhans cell histiocytosis unresponsive to standard therapy.

          -  Other non-malignant hematological disorders in which stem cell transplant with a
             myeloablative regimen is indicated.

          -  Diamond Blackfan Anemia if transfusion dependent

          -  Schwachman Diamond Syndrome: with cytopenias or transformation to myelodysplastic
             syndrome (MDS)

          -  Kostman's Syndrome (if ANC &lt;500 without GCSF support, or transformation to MDS)

          -  Congenital dyserythropoietic anemia if transfusion dependent

          -  Amegakaryocytic thrombocytopenia if baseline platelet counts &lt;20,000 or requiring
             transfusions.

          -  Cardiac, hepatic, renal and pulmonary function deemed adequate for high dose
             chemotherapy with stem cell rescue as per institutional standards. General guidelines
             are as follows:

               -  Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction
                  at rest must be &gt; 40% and must improve with exercise, or shortening fraction by
                  echocardiogram must be within institutional normals

               -  Hepatic: &lt; 3 x normal SGOT and &lt; 2.5 mg/dL serum bilirubin

               -  Renal: Serum creatinine within normal range, or if serum creatinine outside
                  normal range then creatinine clearance or glomerular filtration study should be &gt;
                  50% of normal.

               -  Pulmonary: Asymptomatic or, if symptomatic, diffusing capacity of the lung for
                  carbon monoxide (DLCO) &gt; 45% of predicted (corrected for hemoglobin). For
                  children unable to perform pulmonary function testing, then oxygen saturation
                  should be &gt;95%.

          -  Availability of a suitable allogeneic bone marrow donor as per current institutional
             guidelines for non-T cell depleted hematopoietic stem cell transplant (HSCT).

          -  Patients who have undergone previous stem cell transplant (SCT) and failed engraftment
             or who had relapse of their disease are considered eligible if they meet other
             eligibility criteria and if the second SCT would occur 6 months or more after the
             first. If the first SCT preparative regimen was of a non-myeloablative intensity then
             the second SCT could be performed earlier when the acute toxicity from that procedure
             was resolved.

        Exclusion Criteria:

          -  Patients who are moribund or whose life expectancy is severely limited by disease
             other than their underlying disorder. Karnofsky performance status &lt; 70% or Lansky &lt;
             50% for patients &lt; 16 years.

          -  Patients with hemophagocytic disorders secondary to underlying malignancy.

          -  Patients who have ACTIVE/UNSTABLE disease as defined in Appendix V.

          -  Significant active infections, including Human Immunodeficiency Virus (HIV).

          -  Age &gt; 55 years.

          -  Not providing informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>March 27, 2014</results_first_submitted>
  <results_first_submitted_qc>March 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2014</results_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>T-cell depletion</keyword>
  <keyword>immune deficiencies</keyword>
  <keyword>Busulfan pharmacokinetics</keyword>
  <keyword>Non-Malignant Hematological Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Chediak-Higashi Syndrome</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the clinic or hospital where they were being seen for their disease. The study was discussed with them at the time that treatment options were being presented.</recruitment_details>
      <pre_assignment_details>Patients had to have a suitable donor identified prior to the subject starting the conditioning regimen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intent-To-Treat</title>
          <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intent-To-Treat</title>
          <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Transplant Engraftment</title>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Transplant Engraftment</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Treatment Related Mortality.</title>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Treatment Related Mortality.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Surviving (Disease-free)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Surviving (Disease-free)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade II-IV Graft-Versus-Host Disease (GVHD)</title>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade II-IV Graft-Versus-Host Disease (GVHD)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Graft Failure</title>
        <time_frame>Day 100 Post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Graft Failure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With III-IV Graft-Versus-Host Disease (GVHD)</title>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With III-IV Graft-Versus-Host Disease (GVHD)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Surviving (Disease-free)</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Surviving (Disease-free)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time consent was signed to the end of follow-up, which was 3 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intent-To-Treat</title>
          <description>Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Multi-organ failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Smith</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-2778</phone>
      <email>smith719@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

